Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge

Journal of Infectious Diseases

Volumn 202, Issue 2, 2010, Pages 251-260

  Crowe, Sherry R ^a   Ash, Linda L ^a   Engler, Renata J M ^d   Ballard, Jimmy D ^b   Harley, John B ^a,b,c   Farris, A Darise ^a,b   James, Judith A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; EPITOPE; BACTERIAL TOXIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; PEPTIDE;

ACTIVE IMMUNIZATION; ADULT; ANTHRAX; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BLOOD; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETICS; IMMUNIZATION; IMMUNOLOGY; MACROPHAGE; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; RACE; UNITED STATES; VACCINATION;

ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOTERRORISM; CELL LINE; CONTINENTAL POPULATION GROUPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MACROPHAGES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OKLAHOMA; PEPTIDES; VACCINATION;

EID: 77954584270     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653495     Document Type: Article

References (47)

1. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol 2004; 152:135-164.
2. Gordon VM, Klimpel KR, Arora N, Henderson MA, Leppla SH. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 1995; 63: 82-87.
3. Lacy DB, Wigelsworth DJ, Melnyk RA, Harrison SC, Collier RJ. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc Natl Acad Sci U S A 2004; 101:13147-13151.
4. Starnbach MN, Collier RJ. Anthrax delivers a lethal blow to host immunity. Nat Med 2003; 9:996-997.
5. Firoved AM, Miller GF, Moayeri M, et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 2005; 167:1309-1320.
6. Kumar P, Ahuja N, Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect Immun 2002; 70:4997-5007.
7. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65:5171-5175.
8. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988; 56:1807-1813.
9. Little SF, Leppla SH, Friedlander AM. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun 1990; 58:1606-1613.
10. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 2001; 69:4509-4515.
11. Welkos S, Little S, Friedlander A, Fritz D, Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001; 147:1677-1685. (Pubitemid 32544833)
12. Nguyen ML, Crowe SR, Kurella S, et al. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009; 77:162-169.
13. Quinn CP, Dull PM, Semenova V, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004; 190:1228-1236.
14. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282: 2104-2106.
15. Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300:1532-1543.
16. Pitt ML, Little S, Ivins BE, et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 1999; 87:304.
17. Baillie L, Townend T, Walker N, Eriksson U, Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 2004; 42:267-270.
18. Baillie LW, Fowler K, Turnbull PC. Human immune responses to the UK human anthrax vaccine. J Appl Microbiol 1999; 87:306-308.
19. Quinn CP, Semenova VA, Elie CM, et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103-1110.
20. Mohamed N, Li J, Ferreira CS, et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 2004; 72:3276-3283.
21. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11:85-89.
22. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. J Toxicol Clin Toxicol 2001; 39:85-100.
23. Pittman PR, Leitman SF, Oro JG, et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 2005; 12:713-721.
24. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL,McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006; 24:3654-3660.
25. Chen Z, Moayeri M, Zhou YH, et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 2006; 193:625-633.
26. Cunningham K, Lacy DB, Mogridge J, Collier RJ. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci U S A 2002; 99:7049-7053. (Pubitemid 34527150)
27. Flick-Smith HC, Walker NJ, Gibson P, et al. A recombinant carboxyterminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002; 70:1653-1656.
28. Mourez M, Yan M, Lacy DB, et al. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci U S A 2003; 100:13803-13808. (Pubitemid 37499147)
29. Varughese M, Teixeira AV, Liu S, Leppla SH. Identification of a receptorbinding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun 1999; 67:1860-1865.
30. Reuveny S, White MD, Adar YY, et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001; 69:2888-2893.
31. Hanson JF, Taft SC, Weiss AA. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 2006; 13:208-213.
32. Grunow R, Porsch-Ozcurumez M, Splettstoesser W, et al. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 2007; 25:3679-3683.
33. Hewetson JF, Little SF, Ivins BE, et al. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 2008; 26:4262-4266.
34. Wang F, Ruther P, Jiang I, et al. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies 2004; 13:105-110.
35. Sawada-Hirai R, Jiang I, Wang F, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vac cinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004; 2:5.
36. Albrecht MT, Li H, Williamson ED, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007; 75:5425-5433.
37. Peterson JW, Comer JE, Noffsinger DM, et al. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 2006; 74:1016-1024.
38. Rivera J, Nakouzi A, Abboud N, et al. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 2006; 74:4149-4156.
39. Brossier F, Levy M, Landier A, Lafaye P, Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 2004; 72:6313-6317.
40. Jiao GS, Cregar L, Wang J, et al. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci U S A 2006; 103:19707-19712.
41. Sarac MS, Peinado JR, Leppla SH, Lindberg I. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 2004; 72:602-605.
42. Brossier F, Weber-Levy M, Mock M, Sirard JC. Role of toxin functional domains in anthrax pathogenesis. Infect Immun 2000; 68:1781-1786.
43. Abboud N, De Jesus M, Nakouzi A, et al. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J Biol Chem 2009; 284:25077-25086.
44. Kelly-Cirino CD, Mantis NJ. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 2009; 77:4859-4867.
45. Kaur M, Chug H, Singh H, et al. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol Immunol 2009; 46:2107-2115.
46. Gubbins MJ, Schmidt L, Tsang RS, Berry JD, Kabani A, Stewart DI. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine. J Immunoassay Immunochem 2007; 28:213-225.
47. Zhou B, Carney C, Janda KD. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem 2008; 16:1903-1913.